Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of genomics of myeloma and plasma cell leukemia finds TP53, CCND1, and KRAS mutations in both; DIS3 (17 vs 1%), CCND2 (22 vs 15%), PIK3R1 (6 vs 0%), MAP3K1 (6 vs 2%), IGH::CCND1 and MYC translocations more common in PCL.”
Title: Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability
Authors: Meera Mohan, Natalie Danziger, Othman Salim Akhtar, Ravi Narra, Marcelo C. Pasquini, Sabarinath Venniyil Radhakrishnan, Binod Dhakal, Anita D’Souza, Douglas I Lin, Caleb Ho, Razelle Kurzrock
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
